(BYSI) BeyondSpring Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BYSI) BeyondSpring Inc. Complete Analysis Pack
BeyondSpring’s Business Model, Made Clear
Unlock the full strategic blueprint behind BeyondSpring Inc.’s business model. This concise Business Model Canvas shows how the company creates value, reaches customers, and positions itself in a competitive biotech landscape. Perfect for investors, analysts, and founders who want clear, actionable insight—get the full version for the complete picture.
Partnerships
Bristol Myers Squibb combo assets
BeyondSpring Inc. has used Bristol Myers Squibb’s nivolumab and nivolumab plus ipilimumab as external immuno-oncology inputs in its plinabulin combo strategy, including studies in NSCLC and SCLC. The partnership is clinical, not commercial, and centers on testing regimen fit rather than shared sales; as of 2026, no direct Bristol Myers Squibb revenue tie is disclosed for these assets.
Oncology trial sites
BeyondSpring Inc. depends on oncology trial sites to run Phase III studies in chemotherapy-induced neutropenia and advanced NSCLC, where hospitals and investigator sites recruit eligible patients and collect protocol-driven safety and efficacy data. These late-stage sites are the core execution layer for validating outcomes before any regulatory filing.
Academic cancer centers
BeyondSpring Inc. needs academic cancer centers for NSCLC, SCLC, and radiation-combo trials because these sites handle complex patients and generate publication-grade translational data. With lung cancer still causing about 2.5 million new cases and 1.8 million deaths worldwide, these centers also boost clinical credibility and help recruit the right oncology experts fast.
CRO and trial vendors
BeyondSpring Inc. depends on CROs and trial vendors to run its multicenter oncology studies, covering monitoring, data management, site support, and trial logistics. This matters because clinical-stage biopharma firms can avoid building a large in-house operations team; for context, BeyondSpring’s 2025 filings still show it as clinical-stage with no product revenue.
- Run multicenter oncology trials
- Handle monitoring and data
- Cut in-house ops needs
Manufacturing and supply contractors
BeyondSpring Inc. relies on manufacturing and supply contractors for GMP-controlled production, packaging, and trial supply of plinabulin and pipeline assets. This matters because continuity of supply is critical in oncology trials, where one delayed batch can stall enrollment and data readout.
- Outsourced GMP keeps trial supply moving.
- Supports plinabulin and pipeline compounds.
- Protects continuity across clinical sites.
BeyondSpring’s Key Partners Power Its Late-Stage Oncology Push
BeyondSpring Inc. depends on Bristol Myers Squibb, oncology trial sites, academic cancer centers, CROs, and GMP manufacturers to test plinabulin regimens and move late-stage studies forward. Its 2025 filing still shows clinical-stage status with no product revenue, so these partners are the core execution layer.
| Partner | Role | 2025/2026 note |
|---|---|---|
| Bristol Myers Squibb | Comparator IO drugs | Nivolumab, nivolumab plus ipilimumab |
| Sites, CROs, CMOs | Trials, data, supply | Supports Phase III work |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of BeyondSpring Inc. covering its oncology-focused value proposition, customers, channels, and revenue logic.
Customizable Excel Spreadsheet
BeyondSpring Inc. Business Model Canvas quickly relieves analysis pain by condensing strategy into a clear, editable one-page snapshot.
Reference Sources
Provides a clear source trail for BeyondSpring Inc. data, boosting credibility and speeding investment or strategy decisions.
Activities
Phase III clinical development
BeyondSpring’s core activity is Phase III clinical development, led by two late-stage programs: chemotherapy-induced neutropenia and advanced NSCLC. The value driver is execution, with success tied to patient enrollment, prespecified endpoint hits, and clean data readouts that can support regulatory filing.
Combination oncology trials
BeyondSpring Inc. is running Plinabulin combination oncology trials with nivolumab, nivolumab plus ipilimumab, and PD-1 or PD-L1 antibodies plus radiation, building on a 3-path combo strategy to move beyond monotherapy. This work spans multiple tumor types and is meant to widen Plinabulin’s use in hard-to-treat solid tumors.
Preclinical small-molecule discovery
BeyondSpring Inc. is advancing 3 preclinical-stage small-molecule immune agents, with early discovery work covering screening, lead optimization, and candidate selection to extend the pipeline beyond Plinabulin. This stage is capital-light versus clinical development, but it is the key source of future assets before IND-enabling studies and first-in-human trials.
Translational immune mechanism work
BeyondSpring Inc.'s translational immune mechanism work centers on plinabulin, a selective immune-modulating and microtubule-binding agent. These studies link immune activation to cancer response, helping the Company sharpen biomarker strategy and pick the best indications for later-stage development.
- Guides biomarker-driven trial design
- Supports indication selection
- Links immune activation to response
- De-risks late-stage development
That matters because plinabulin's value depends on proving who responds, why they respond, and where the drug can win in cancer care.
Regulatory and IP development
BeyondSpring Inc.’s regulatory and IP work centers on Plinabulin, a clinical-stage asset still needing active FDA planning and patent defense. These activities keep the program viable for approval talks, and they also matter in financing and partnering because a stronger patent life and cleaner regulatory path can improve deal terms.
- Protects Plinabulin’s commercial runway
- Supports FDA pathway planning
- Strengthens partnering leverage
BeyondSpring’s Pipeline: 2 Late-Stage Programs, 3 Combo Paths, 3 Early Agents
BeyondSpring Inc.’s key activities are late-stage Plinabulin development, combo-trial execution, and early pipeline discovery. The work spans 2 late-stage programs, 3-path oncology combinations, and 3 preclinical small-molecule immune agents, with biomarker and regulatory work used to sharpen trial design and protect the asset path.
| Activity | Data |
|---|---|
| Late-stage trials | 2 programs |
| Combo strategy | 3-path |
| Early pipeline | 3 agents |
Full Document Unlocks After Purchase
Business Model Canvas
This BeyondSpring Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a real section of the final file. After checkout, you’ll get the same fully formatted document, ready to edit, present, or share.
Resources
Plinabulin asset
Plinabulin is BeyondSpring Inc. flagship asset and the core clinical and commercial resource in its Business Model Canvas. It anchors two lead programs, chemotherapy-induced neutropenia and combination oncology studies, including phase 3 development in non-small cell lung cancer, so its value drives the companys pipeline and partnering case.
Phase III clinical data
BeyondSpring Inc. has 2 Phase III data sets for plinabulin: chemotherapy-induced neutropenia prevention and advanced NSCLC. In biopharma, late-stage readouts are the key value trigger because they can reduce regulatory risk, support partner deals, and shape investor pricing.
Proprietary development platform
BeyondSpring Inc.'s proprietary development platform is the core resource behind its oncology pipeline, built to design and advance immune-based cancer agents rather than depend on one drug. In its latest public filings, the platform has supported the progression of multiple programs, including plinabulin-based development work across Phase 2 and Phase 3 studies.
Three preclinical immune agents
BeyondSpring Inc.'s key resources also include three preclinical small-molecule immune agents, giving the company 3 earlier-stage shots on goal beyond Plinabulin. These assets add future pipeline optionality and reflect retained IP and scientific know-how at a stage where value is still driven more by data than revenue.
- 3 preclinical immune agents
- Earlier-stage IP and know-how
- Future optionality beyond Plinabulin
New York headquarters and team
BeyondSpring is headquartered in New York, New York, and that base supports management, financing, and strategic oversight. Its scientific and development team is the core resource, which matters in a clinical-stage model where capital use and trial execution drive value.
- New York HQ anchors leadership.
- Team drives R&D execution.
- Capital discipline is key.
BeyondSpring's Value Hinges on Plinabulin's 2 Phase III Programs
BeyondSpring Inc.'s key resources are plinabulin, its proprietary oncology platform, and a small pipeline of 3 preclinical immune agents. The company also relies on its New York based team to run late stage trials and protect IP, with 2 Phase III plinabulin programs still driving value.
| Key resource | Data |
|---|---|
| Plinabulin | 2 Phase III programs |
| Preclinical assets | 3 immune agents |
| HQ | New York, New York |
Value Propositions
CIN prevention
BeyondSpring Inc.’s plinabulin advanced through Phase III for preventing chemotherapy-induced neutropenia, a complication that can drive dose delays in up to 30% to 40% of patients on myelosuppressive regimens. Its value is clear: maintain neutrophil counts, reduce infection risk, and help keep cancer treatment on schedule.
Advanced NSCLC treatment
Plinabulin’s Phase III advance in advanced NSCLC gives BeyondSpring Inc. a second late-stage oncology use and widens the drug’s clinical reach beyond CINV. Advanced NSCLC is a huge need area: lung cancer caused about 2.5 million new cases worldwide in 2022, so even modest uptake can matter.
Immune-modulating plus microtubule-binding
Plinabulin pairs immune modulation with microtubule binding, giving BeyondSpring Inc. a dual profile that is different from standard supportive-care drugs and many oncology agents. That matters because it can target both anti-cancer activity and chemotherapy support; in DUBLIN-3, overall survival was 10.6 months with plinabulin plus docetaxel versus 8.6 months with docetaxel alone.
Combination with IO and radiation
BeyondSpring Inc. is studying Plinabulin in 3 combo paths: with nivolumab, nivolumab plus ipilimumab, and PD-1 or PD-L1 antibodies plus radiation. That widens response potential across more tumor types and settings, while pairing with checkpoint therapy and radiation may lift efficacy where single agents fall short.
- 3 combo programs under study
- Targets broader cancer indications
- Aims to improve response rates
- Uses IO and radiation synergy
Broad oncology pipeline
BeyondSpring Inc.’s value proposition is a broad oncology pipeline, not a single drug bet. Its mix of preclinical immune agents and multiple clinical combinations gives the Company more shots at success and helps spread risk across several cancer settings.
- Not tied to one indication
- Includes preclinical immune agents
- Uses multiple clinical combinations
- Creates long-term optionality
BeyondSpring’s Dual-Use Plinabulin Fuels a Broader Clinical Moat
BeyondSpring Inc.’s value proposition is plinabulin’s dual use: supportive care to help prevent chemotherapy-induced neutropenia and a late-stage oncology asset with NSCLC and multiple combination readouts. That gives the Company a broader clinical moat, with DUBLIN-3 showing overall survival of 10.6 months versus 8.6 months for docetaxel alone.
| Metric | Value |
|---|---|
| DUBLIN-3 OS | 10.6 vs 8.6 months |
| Combo programs | 3 |
Customer Relationships
Hospital trial relationships
BeyondSpring Inc. depends on oncology hospitals and investigator sites to enroll patients, and these ties are built around protocol follow-up, safety oversight, and strict data capture. That makes them long-cycle and research-heavy: each site has to screen, dose, report adverse events, and keep trial records aligned with regulators.
Scientific investigator support
BeyondSpring Inc. builds scientific-investigator ties with oncology experts who run and read the studies, so medical depth and clean trial execution matter. These links matter most when data move into publication and clinical use, because peer review, congress abstracts, and journal uptake drive adoption.
Pharma collaboration management
BeyondSpring Inc. manages pharma collaborations as a high-trust, multi-year model built around Phase 2/3 combination studies, where external drug owners and development partners must stay aligned on study design, data sharing, and go/no-go priorities. This keeps progress tied to shared endpoints and partner confidence, not just one-off transactions.
Because combo programs can involve 2 or more organizations across development, the relationship is less about sales and more about coordinated execution and risk sharing.
Medical affairs dialogue
BeyondSpring Inc. relies on medical affairs dialogue with oncologists to explain mechanism of action, endpoints, and clinical positioning; this is a technical relationship, not a consumer one, and it supports scientific credibility and future uptake. In oncology, that matters because treatment choices are driven by evidence and protocol fit, not brand pull.
- Oncologist-led, data-heavy engagement
- Explains endpoints and positioning
- Builds credibility for adoption
Investor communication
BeyondSpring Inc. keeps investor communication tight because it is a clinical-stage public biopharma with no steady product sales and needs capital to fund trials. The market follows its quarterly 10-Q/10-K filings, 4 earnings updates a year, and trial readouts, so each update can move the stock fast.
- Trial data drives market views.
- Pipeline news affects valuation.
- Financing updates shape runway.
BeyondSpring’s Trust Engine: Sites, Partners, and Investors
BeyondSpring Inc. uses long-cycle, data-led relationships with oncology sites, investigators, pharma partners, and oncologists; trust is built through protocol execution, safety reporting, and published trial results. As a clinical-stage biopharma, investor ties also stay tight because trial readouts and financing shape runway.
| Relationship | Core driver | FY2025/2026 note |
|---|---|---|
| Sites | Enrollment | Trial-based |
| Partners | Risk sharing | Multi-year |
| Investors | Runway | Readout-driven |
Channels
Clinical trial sites
Clinical trial sites are BeyondSpring Inc.'s main execution channel for Plinabulin studies, linking the company to eligible cancer patients and the clinical data needed for readouts. They are critical for Phase III and combination trials, where patient enrollment, protocol adherence, and site quality can decide speed and data strength.
Academic cancer centers
Academic cancer centers are a key channel for BeyondSpring Inc. in complex oncology trials because they host specialist investigators, trial labs, and publication pipelines. In the U.S., 72 NCI-designated centers, including 57 comprehensive centers, are well suited for NSCLC, SCLC, and radiation studies where high-acuity patients and protocol depth matter.
Pharma collaboration channels
BeyondSpring uses direct licensing and clinical collaboration to reach development partners, especially for combo studies with external immuno-oncology drugs. These channels matter for pipeline expansion because they let Company Name test more partners without building each asset alone.
Medical congresses
BeyondSpring Inc. uses oncology congresses and scientific meetings to present clinical results and mechanism data, reaching the core buyer group of oncologists and researchers. Major meetings such as ASCO draw over 40,000 oncology professionals, making this a high-signal channel for awareness and peer validation.
- Show clinical efficacy data
- Explain mechanism of action
- Build oncologist trust fast
Investor relations and corporate communications
BeyondSpring Inc. uses investor relations and corporate communications to update the market on trial readouts, pipeline progress, and strategy; as a clinical-stage company with 0 marketed products, this channel is central to capital formation and visibility. Its news flow helps investors price development risk and track execution between milestones.
- Trial updates drive investor attention.
- Pipeline news supports funding access.
- No products means heavy disclosure needs.
BeyondSpring’s Clinical Network Powers Plinabulin Growth
BeyondSpring Inc.’s main channels are clinical trial sites, academic cancer centers, and partner-led combo studies, which together drive patient enrollment, protocol execution, and data readouts for Plinabulin. Scientific meetings and investor relations extend reach, with ASCO drawing over 40,000 oncology professionals and the Company maintaining 0 marketed products, so disclosure is key.
| Channel | Key data |
|---|---|
| Clinical sites | Phase III enrollment |
| Academic centers | 72 NCI centers |
| ASCO | 40,000+ attendees |
Customer Segments
Patients at risk of chemotherapy-induced neutropenia
Patients at risk of chemotherapy-induced neutropenia are cancer patients on myelosuppressive regimens, where grade 3/4 neutropenia can hit 40% to 80% of high-risk cases. They are the direct users of BeyondSpring Inc.'s Plinabulin supportive-care use, seeking fewer infections, safer dosing, and fewer chemo delays.
Advanced NSCLC patients
BeyondSpring Inc.'s Plinabulin Phase III NSCLC program targets advanced non-small cell lung cancer, a segment that makes up about 85% of lung cancer cases and often presents at late stage, when cure is unlikely. The value is measured by better response and longer survival, especially in a disease that still causes about 1.8 million deaths worldwide each year.
SCLC patients in combination studies
BeyondSpring targets a small, high-risk small cell lung cancer pool: SCLC makes up about 10% to 15% of lung cancers, and U.S. incidence is roughly 30,000 cases a year. Its combination work with nivolumab and ipilimumab serves a research-only segment, aimed at patients with few durable options rather than approved sales.
Oncologists and cancer hospitals
Oncologists and cancer hospitals are BeyondSpring Inc.'s key B2B2C customers: they decide trial enrollment and later clinical use, so they care most about efficacy, safety, and protocol fit. In 2025, cancer still drove about 10 million deaths worldwide, which keeps pressure on hospitals to adopt therapies that show clear benefit in real patients.
- Trial gatekeepers and adoption decision-makers
- Focus on efficacy, safety, protocol fit
- Need evidence from real-world use
Pharma partners and research institutions
BeyondSpring Inc.’s direct commercial counterparties are pharma developers and research institutions, because it still has 0 marketed products and needs partners for combination studies, licensing, and discovery work. These deals matter most while the Company stays clinical-stage, since they can fund trials and validate the science before any commercial launch.
- Drug developers drive combo-study demand
- Institutions support discovery and validation
- Licensing can bring non-dilutive cash
BeyondSpring Targets Critical Oncology Needs in a High-Burden Cancer Market
BeyondSpring Inc. serves three core groups: high-risk cancer patients needing neutropenia prevention, NSCLC/SCLC patients in late-stage oncology trials, and hospitals and oncologists who decide adoption based on safety and efficacy. In 2025, cancer caused about 10 million deaths worldwide, keeping demand for better supportive care and trial-backed oncology options high.
| Segment | Need | Key 2025/2026 fact |
|---|---|---|
| Patients | Fewer infections | Grade 3/4 neutropenia can reach 40% to 80% |
| Hospitals | Protocol fit | About 10 million cancer deaths in 2025 |
Cost Structure
Phase III trial costs
Phase III oncology trials are one of BeyondSpring Inc.’s biggest cost items, often running $20 million to $100 million+ per study because they need multicenter enrollment, long follow-up, and tight safety monitoring. Costs include site payments, data management, CRO oversight, and patient retention, so trial operations stay a core cash drain.
R and D personnel
Scientists, clinical developers, and regulatory staff are key fixed costs for BeyondSpring Inc., because Plinabulin and its preclinical pipeline need in-house expertise to run trials and file with regulators. In FY2025, R&D stayed the company’s main cash drain, with personnel costs recurring each period as long as these programs stay active.
Preclinical research spending
BeyondSpring Inc. still has to fund discovery and early testing for its three small-molecule immune agents, including assay development, lead optimization, and animal studies. These preclinical costs come before any clinical-stage upside, so they are a pure R&D cash use at this stage.
Regulatory and quality expenses
For BeyondSpring Inc., regulatory and quality expenses are non-discretionary: clinical-stage biopharma must fund filings, compliance, audits, and quality systems to keep trials active and support FDA and partner review. These costs usually rise with each study milestone, since GMP and QMS controls are needed before any approval path can advance.
- Cover submissions and agency replies
- Support GMP and QMS controls
- Reduce partner diligence risk
Corporate and public-company overhead
BeyondSpring Inc. carries fixed corporate overhead from its New York headquarters, legal, finance, audit, and investor-relations teams. As a public company, it also pays recurring governance, SEC reporting, and board costs; these expenses continue even when no products are marketed, so they can weigh on cash burn and operating loss.
- New York HQ and staff overhead
- Legal, audit, and finance costs
- SEC filing and board governance costs
- Costs persist without product sales
BeyondSpring’s FY2025 Costs Stay R&D-Heavy as Cash Burn Remains High
BeyondSpring Inc.’s cost structure is still dominated by R&D, with FY2025 spending tied to Phase III oncology trials, preclinical work, regulatory filings, and a lean clinical team. Public-company overhead also keeps cash burn high, even without product sales.
| Cost item | FY2025 |
|---|---|
| R&D | Main cash drain |
| Phase III trials | $20M-$100M+ per study |
| HQ and G&A | Recurring fixed cost |
Revenue Streams
No marketed product sales
BeyondSpring Inc. is still clinical-stage, so it does not generate revenue from marketed product sales; the latest reported figure for this line item is $0. Revenue is not tied to an approved oncology franchise, so pipeline progress and regulatory milestones are the main value drivers, while 2025/2026 results remain dominated by R&D spending and financing activity.
Licensing income
BeyondSpring Inc. reported $0 revenue in its latest filings, so any Plinabulin or combination-rights license could add immediate upfront cash and later royalties. That fits a standard asset-heavy biopharma model, where one deal can bring millions in upfront fees before any product sales.
Milestone payments
BeyondSpring Inc.'s milestone payments can bring cash from development, regulatory, and commercial triggers, like Phase 3 readouts or FDA approval. In a partnership-led oncology model, this can be more important than product sales; BeyondSpring's revenue has been minimal, so each partner event can matter a lot.
Research collaboration funding
Research collaboration funding lets BeyondSpring Inc. shift part of combination-study and discovery costs to external partners, which can reduce R and D cash burn. This is most useful in multi-asset programs, where one collaborator may fund shared preclinical work, early clinical design, or data analysis.
- Offsets part of R and D spend
- Fits multi-asset combination programs
- Supports shared discovery work
Future commercialization of Plinabulin
If approved, Plinabulin could turn BeyondSpring Inc. from a development-stage biotech into a product-sales business, with revenue from chemotherapy-induced neutropenia (CIN) and oncology uses. Until then, the company still relies on financing and partner support, so commercialization is the main long-term revenue path but not yet booked revenue.
- Near-term: development funding
- Mid-term: CIN launch revenue
- Long-term: oncology product sales
BeyondSpring’s Revenue Hinges on Partnerships, Not Product Sales
BeyondSpring Inc. had $0 revenue in its latest 2025/2026 filings, so current cash inflow comes from partner funding, collaboration payments, and potential milestone fees rather than product sales. If Plinabulin is approved, revenue could shift to product sales, upfront license fees, and royalties.
| Stream | 2025/2026 data |
|---|---|
| Product sales | $0 |
| Partner funding | Ongoing |
| Milestones / royalties | Potential, not booked |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.